Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vertex Targeting Protein Degradation In $1bn Kymera Deal

16 May 2019

• By John Davis

RubbishBags — A new therapeutic approach involves using the way cells tag unwanted proteins for recycling • Source: Shutterstock

Related Content

Vertex Pain Product VX-150 Comes Out Of The Shadows

19 Dec 2018

Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group

25 Apr 2018

AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal

15 Nov 2018

Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services

16 Nov 2018

Related Companies

Vertex Pharmaceuticals Incorporated

Kymera Therapeutics, Inc.

GSK plc

Bristol Myers Squibb Company

Genentech, Inc.

AbbVie Inc.

C4 Therapeutics, Inc.

CRISPR Therapeutics AG

Additional Topics

Deals Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.